Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO

Moderna is in no rush to conduct an IPO, but the secretive biopharma unicorn gave potential investors in a future offering a glimpse of its 12 programs in or nearing the clinic at J.P. Morgan’s annual conference.

LabmicroscopeDNAgel_1200x675

Moderna Therapeutics LLC has become one of the biopharmaceutical industry’s biggest unicorns – attracting billions of dollars in venture, partnership and grant funding – while revealing few details about its messenger RNA (mRNA) therapeutic platform. But the normally secretive company subjected its pipeline to public scrutiny during an appearance at the J.P. Morgan Healthcare Conference.

Scrip spoke with Moderna CEO Stephane Bancel about before and after the standing-room-only Jan. 9 J.P. Morgan presentation, which was...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip